| Title | Experimental Hematology and Oncology |
| Abbreviation | Exp. Hematol. Oncol. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Cancer Research (Q1); Hematology (Q1); Oncology (Q1) |
| h-index | 47 |
| Overall Rank/Ranking | 672 |
| SCImago Journal Rank (SJR) | 3.092 |
| Impact Score | 8.39 |
| Publisher | BioMed Central Ltd |
| Country | United Kingdom |
| ISSN | 21623619 |
| Best Quartile | Q1 |
| Coverage History | 2012-2025 |
Experimental Hematology and Oncology is a journal covering the technologies/fields/categories related to Cancer Research (Q1); Hematology (Q1); Oncology (Q1). It is published by BioMed Central Ltd. The overall rank of Experimental Hematology and Oncology is 672. According to SCImago Journal Rank (SJR), this journal is ranked 3.092. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 47. The best quartile for this journal is Q1.
The ISSN of Experimental Hematology and Oncology journal is 21623619. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Experimental Hematology and Oncology is cited by a total of 2136 articles during the last 3 years (Preceding 2024).
The Impact IF 2024 of Experimental Hematology and Oncology is 8.39, which is computed in 2025 as per its definition. Experimental Hematology and Oncology IF is increased by a factor of 2.24 and approximate percentage change is 36.42% when compared to preceding year 2023, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2024 of Experimental Hematology and Oncology is 8.39. If the same upward trend persists, Impact IF may rise in 2025 as well.
| Year | Impact IF |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 8.39 |
| 2023 | 6.15 |
| 2022 | 8.65 |
| 2021 | 7.07 |
| 2020 | 4.27 |
| 2019 | 3.65 |
| 2018 | 3.02 |
| 2017 | 2.97 |
| 2016 | 3.19 |
| 2015 | 2.51 |
| 2014 | 2.93 |
Experimental Hematology and Oncology has an h-index of 47. It means 47 articles of this journal have more than 47 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Experimental Hematology and Oncology is 21623619. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Experimental Hematology and Oncology is 672. According to SCImago Journal Rank (SJR), this journal is ranked 3.092. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 3.092 |
| 2023 | 2.384 |
| 2022 | 1.908 |
| 2021 | 1.301 |
| 2020 | 1.223 |
| 2019 | 0.941 |
| 2018 | 0.988 |
| 2017 | 0.842 |
| 2016 | 0.992 |
| 2015 | 0.971 |
| 2014 | 0.845 |
| Year | Ranking |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 672 |
| 2023 | 1008 |
| 2022 | 1427 |
| 2021 | 2682 |
| 2020 | 3207 |
| 2019 | 4738 |
| 2018 | 4436 |
| 2017 | 5477 |
| 2016 | 4475 |
| 2015 | 4626 |
| 2014 | 5370 |
Experimental Hematology and Oncology is published by BioMed Central Ltd. It's publishing house is located in United Kingdom. Coverage history of this journal is as following: 2012-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Experimental Hematology and Oncology is Exp. Hematol. Oncol.. This abbreviation ('Exp. Hematol. Oncol.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Cancer Research (Q1); Hematology (Q1); Oncology (Q1), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Experimental Hematology and Oncology latest impact IF is 8.39. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 8.65 (2022) and 2.51 (2015), respectively, in the last 11 years. Moreover, its average IS is 4.8 in the previous 11 years.
The Experimental Hematology and Oncology has an SJR (SCImago Journal Rank) of 3.092, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 3.092 in 2024 and the lowest being 0.842 in 2017. Furthermore, the average SJR of the Experimental Hematology and Oncology over the previous 11-year period stands at 4.8.
The latest h-index of the Experimental Hematology and Oncology is 47.
The Experimental Hematology and Oncology is published by the BioMed Central Ltd, with its country of publication being the United Kingdom.
The Experimental Hematology and Oncology is currently ranked 672 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 672 in 2024 and its lowest position of 5477 in 2017.
The standard ISO4 abbreviation for the Experimental Hematology and Oncology is Exp. Hematol. Oncol..
Experimental Hematology and Oncology is classified as a journal that the BioMed Central Ltd publishes.
The Experimental Hematology and Oncology encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Experimental Hematology and Oncology is assigned the following International Standard Serial Numbers (ISSN): 21623619.
The best quartile for the Experimental Hematology and Oncology is Q1 (2024).
The Experimental Hematology and Oncology coverage history can be summarized as follows: 2012-2025.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Journal of Academic Ethics | journal | 8704 | Springer Netherlands | 34 | 4.04 |
| Historia | journal | 22470 | Universidade Estadual Paulista | 9 | 0.16 |
| Journal of Geriatric Physical Therapy | journal | 8686 | Lippincott Williams and Wilkins Ltd. | 53 | 1.55 |
| Journal of Supply Chain Management | journal | 331 | Wiley-Blackwell | 119 | 9.76 |
| Materials Research | journal | 15597 | Universidade Federal de Sao Carlos | 75 | 1.40 |
| Discourse | journal | 7536 | Routledge | 70 | 2.75 |
| Biological Procedures Online | journal | 5232 | BioMed Central Ltd | 51 | 4.00 |
| Journal of Immigrant and Refugee Studies | journal | 7357 | Routledge | 39 | 2.17 |
| Journal des Professionnels de l'Enfance | journal | 30098 | TPMA | 2 | 0.00 |
| Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining | conference and proceedings | 4334 | 192 | 0.00 |
| Year | Impact Score (IS) |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 8.39 |
| 2023 | 6.15 |
| 2022 | 8.65 |
| 2021 | 7.07 |
| 2020 | 4.27 |
| 2019 | 3.65 |
| 2018 | 3.02 |
| 2017 | 2.97 |
| 2016 | 3.19 |
| 2015 | 2.51 |
| 2014 | 2.93 |
